Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Sanjay Shukla — FY2025 total compensation $3,456,253

Sanjay Shukla is President and Chief Executive Officer of aTYR PHARMA INC (ATYR). The company reported total compensation of $3,456,253 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$638,977
Bonus$0
Stock awards$0
Option awards$2,595,200
Non-equity incentive plan$210,862
Pension and non-qualified deferred compensation$0
All other compensation$11,214
Total$3,456,253

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure aTYR PHARMA INC filed March 26, 2026, accession 0001339970-26-000021.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025President and Chief Executive Officer$638,977$0$0$2,595,200$210,862$0$11,214$3,456,253
FY2024President and Chief Executive Officer$580,887$0$0$641,760$246,877$0$10,998$1,480,522

Totals as disclosed in each year's own compensation disclosure for aTYR PHARMA INC.

03

Peer context

Peer-group chief executive median$5,094,999
Difference from that median$-1,638,746
Percentile within the disclosed peer group33rd
Peers with a disclosed figure7

Medians and percentiles are computed across the peer group aTYR PHARMA INC discloses in its own compensation disclosure.

04

The other named executive officers of aTYR PHARMA INC

Named executive officerRoleFY2025 total
Sanjay Shukla this pagePresident and Chief Executive Officer$3,456,253
Jill BroadfootChief Financial Officer$1,309,913
Nancy DenyesGeneral Counsel and Corporate Secretary$1,284,841

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full aTYR PHARMA INC compensation brief.

05

The company page

Sanjay Shukla's compensation sits inside aTYR PHARMA INC's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The aTYR PHARMA INC (ATYR) compensation brief